R&D | April 23, 2026
Sanplatec selects Mitsubishi Chemical’s Zelas TPS for new cell culture tubes
Sanplatec is leading the industry in the field of containers and devices for cell culture and live transport
Sanplatec is leading the industry in the field of containers and devices for cell culture and live transport
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Subscribe To Our Newsletter & Stay Updated
